Since my strong buy rating , Oscar Health (NYSE: OSCR ), is up 21%, well ahead of the S&P 500’s 4%. With a valuation multiple of just ~0.45x revenues versus peers at 3.19x, Oscar still offers considerable upside. TheHi, I'm Yiannis. Spotting winners before they break out is what I do best.Experience: Previously worked at Deloitte and KPMG in external/internal auditing and consulting. Education: Chartered Certified Accountant, Fellow Member of ACCA Global, with BSc and MSc degrees from U.K. business schools. ...